Antibe Therapeutics (Antibe Therapeutics) EV-to-FCF : 2.12 (As of Apr. 30, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Antibe Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Antibe Therapeutics's Enterprise Value is $-28.68 Mil. Antibe Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-13.54 Mil. Therefore, Antibe Therapeutics's EV-to-FCF for today is 2.12.

The historical rank and industry rank for Antibe Therapeutics's EV-to-FCF or its related term are showing as below:

ATBPF' s EV-to-FCF Range Over the Past 10 Years
Min: -1323.73 Med: -5.46 Max: 580.9
Current: 2.15

During the past 12 years, the highest EV-to-FCF of Antibe Therapeutics was 580.90. The lowest was -1323.73. And the median was -5.46.

ATBPF's EV-to-FCF is ranked better than
54.62% of 390 companies
in the Biotechnology industry
Industry Median: 4.475 vs ATBPF: 2.15

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-30), Antibe Therapeutics's stock price is $0.2156. Antibe Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.261. Therefore, Antibe Therapeutics's PE Ratio for today is At Loss.

Antibe Therapeutics EV-to-FCF Historical Data

The historical data trend for Antibe Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics EV-to-FCF Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EV-to-FCF

Get a 7-Day Free Trial

-9.07

-15.45

-1,533.03

0.81

0.45

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-FCF	Get a 7-Day Free Trial															1.06	0.45	0.62	0.12	-1.32

Competitive Comparison of Antibe Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Antibe Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's EV-to-FCF falls into.

Antibe Therapeutics EV-to-FCF Calculation

Antibe Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF	=	Enterprise Value (Today)	/	Free Cash Flow (TTM)
	=	-28.676	/	-13.543
	=	2.12

Antibe Therapeutics's current Enterprise Value is $-28.68 Mil.
Antibe Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.54 Mil.

Antibe Therapeutics (OTCPK:ATBPF) EV-to-FCF Explanation

Antibe Therapeutics's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.2156	/	-0.261
	=	At Loss

Antibe Therapeutics's share price for today is $0.2156.
Antibe Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.261.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Antibe Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics (Antibe Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (OTCPK:ATBPF) » Definitions » EV-to-FCF

Comparable Companies

Traded in Other Exchanges

ATE:Canada

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.